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Summary
Objective: The aim of the present study was to investigate gene expression during the in vitro redifferentiation process of human articular
chondrocytes isolated from clinical samples from patient undergoing an autologous chondrocyte transplantation therapy (ACT).
Method: Monolayer (ML) expanded human articular chondrocytes from four donors were cultured in a 3D pellet model and the redifferentiation
was investigated by biochemistry, histology, immunohistochemistry and microarray analysis.
Results: The culture expanded chondrocytes redifferentiated in the pellet model as seen by an increase in collagen type II immunoreactivity
between day 7 and 14. The gene expression from ML to pellet at day 7 included an increase in cartilage matrix proteins like collagen type XI,
tenascin C, dermatopontin, COMP and ﬁbronectin. The late phase consisted of a strong downregulation of extracellular signal-regulated
protein kinase (ERK-1) and an upregulation of p38 kinase and SOX-9, suggesting that the late phase mimicked parts of the signaling
processes involved in the early chondrogenesis in limb bud cells. Other genes, which indicated a transition from proliferation to tissue
formation, were the downregulated cell cycle genes GSPT1 and the upregulated growth-arrest-speciﬁc protein (gas). The maturation of the
pellets included no signs of hypertrophy or apoptosis as seen by downregulation of collagen type X, Matrix Gla protein and increased
expression of caspase 3.
Conclusion: Our data show that humanarticular chondrocytes taken fromsurplus cells of patient undergoingACT treatment andexpanded inML,
redifferentiate and form cartilage likematrix in vitroand that this dynamic process involves genes known to be expressed in early chondrogenesis.
 2004 OsteoArthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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International
Cartilage
Repair
SocietyIntroduction
Articular cartilage is an avascular tissue with limited or no
potential of self-repair. Lesions in adult cartilage caused by
trauma will eventually lead to erosion of the cartilage surface
and development of osteoarthritis (OA). In contrast to the
adult cartilage, the embryonic cartilage has the ability
to repair1. Based on these ﬁndings one strategy in the
promising ﬁeld of tissue engineering related to cartilage
regeneration is to try to mimic the embryonic events of
chondrogenesis during joint formation by applying speciﬁc
growth factors, progenitor cells2 or combinations thereof.
The use of autologous culture expanded chondrocytes for
repair of cartilage lesions in adults was ﬁrst reported from our
laboratory in 19943. In this method, mature chondrocytes are
released from their surrounding matrix and proliferated in
culture dishes under the inﬂuence of serum. During this
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their shape as well as their metabolic state and program
of matrix biosynthesis4e6. Generally, downregulated synthe-
ses of cartilage-speciﬁc proteoglycans and protein markers,
such as collagen type II, are seen as signs of chondrocyte
dedifferentiation4.
The dedifferentiated chondrocytes are able to redifferen-
tiate and upregulate the synthesis of cartilagematrix proteins
when placed in 3D cultures such as ‘‘pellet’’ cultures7e9. The
pellet system has also been used within chondrogenic
differentiation studies of embryonic limb bud cells10 and
mesenchymal stem cells (MSC s)11 isolated from bone
marrow12,13.
More recently, microarray technology has been increas-
ingly applied during in vitro cartilage and bone formation to
decipher the signals that trigger and control speciﬁc
molecular events of differentiation14e19. Considering the
enormous complexity of such differentiation pathways in-
volving a large number of genes, simultaneous gene ex-
pression proﬁling of hundreds to thousands of genes by
means of microarrays is well suited to better understand the
underlying mechanisms20.
Thanks to microarrays and other cutting edge technolo-
gies, the old concepts of linear and irreversible stem cell
differentiation have to be revisited and replaced these days
by new evolving concepts of stem cell plasticity21. We22 and
526 T. Tallheden et al.: Redifferentiation of chondrocytesothers23,24 have recently shown that even adult human
articular chondrocytes show some phenotypic plasticity.
Once dedifferentiated in monolayer (ML), it was demon-
strated that multiclonal populations of adult human chon-
drocytes could be differentiated into the chondrogenic,
osteogenic, and adipogenic lineage.
In the present study we asked the question whether
culture expanded chondrocytes express embryonic genes
during redifferentiation in vitro, which would further support
the hypothesis of the existence of progenitor cells within
adult articular cartilage.
Material and methods
CELL CULTURE
Surplus chondrocytes from patients (age 32e41) un-
dergoing autologous chondrocyte transplantation (ACT)3
were cultured in a 3D pellet culture system as described
earlier12,13. Brieﬂy, 2:0!105 cells from passage 1 (maxi-
mum 7 cell doublings), were placed into polypropylene
conical tubes with 0.5 ml of deﬁned medium, consisting of
DMEM-HG (PAA Laboratories, Linz, Austria) supplemented
with ITS-G (Life Technologies, Sweden), 5.0 mg/ml linoleic
acid (SigmaeAldrich, Stockholm), 1.0 mg/ml human serum
albumin (HSA [Equitech-Bio, TX, USA]), 10 ng/ml TGF-b1
(R&D Systems, UK), 107 M dexamethasone (Sigma),
14 mg/ml ascorbic acid (Sigma) and PenicillineStreptomicin
(PEST [PAA lab.]). The cells were centrifuged at 500 g for
5 min and maintained at 37(C in 7% CO2/93% air. The
medium was changed twice a week.
HISTOLOGY OF PELLETS
On day 7 and 14 the pellets were ﬁxed in Histoﬁx
(Histolab products AB, Sweden), dehydrated in increasing
concentrations of ethanol and embedded in parafﬁn. Five
micrometer sections were cut and placed onto microscope
slides (Superfrost Plus, Menzel-Gla¨ser, Germany), depar-
afﬁnized and stained with Alcian blue/van Gieson and
Safranin-O or immunoassayed with anti-type I and II
collagen, as described below. The stained sections were
analyzed by a Nikon microscope.
IMMUNOHISTOCHEMISTRY OF PELLETS
Sections were deparafﬁnized with decreasing amounts of
ethanol, digested with hyaluronidase, 8000 units/ml (Sigma)
in 0.1 M phosphate buffered saline (PBS) for 60 min at 37(C,
blocked with 3% BSA (Sigma) in PBS for 5 min. The primary
monoclonal antibodies (anti-collagen type I and II (ICN
Biomedicals, Aurora, OH)) were diluted 1:200 in PBS
containing 3% BSA and incubated with the sections for 1 h
at room temperature. The secondary antibody (FITC
conjugated goat anti-mouse), diluted 1:100, was incubated
for 1 h and after rinsing the sections were mounted with
ﬂuorescence mounting medium. The sections were then
analyzed with Nikon ﬂuorescence microscope and digital
pictureswere takenwith theACT-1 software. By usingAdobe
Photoshop, the pictures of collagen type I staining were
changed into a pseudo color and mounted together with the
collagen type II picture.
BIOCHEMICAL ANALYSIS OF PELLETS
On day 7 and 14, pellets were digested with papain
(Sigma) solution (0.3 mg papain/ml sodium phosphate buffer[20 mM] with 1 mMEDTA and 2 mM dithiothreitol) for 60 min
at 60(C. The digested pellets were then mechanically
dissolved by vortex and further analyzed for DNA, glycos-
aminoglycan (GAG) and hydroxyproline content.
The amount of DNA was measured with CyQuant cell
proliferation assay kit (Molecular Probes, Eugene, OR),
according to the manufacturer’s instruction.
The GAG content was measured spectrophotometrically
at 515 nm using dimethylmethylene blue assay25, with
chondroitin sulphate as a standard, and normalized to the
DNA amount in the pellet.
Hydroxyproline, as a measurement of total collagen in the
digested pellet, was analyzed with a modiﬁed method as
described earlier26. Brieﬂy, digested pellets were hydrolyzed
over night with 6 N hydrochloric acid at 127(C and then
dissolved in assay buffer ([3:2:10] n-propanol, deionized
water and stock buffer, pH 6.1 (0.24 M citric acid, 0.88 M
sodium acetate trihydrate, 0.88 M anhydrous sodium ace-
tate, 0.21 M acetic acid and 0.85 M sodium hydroxide)). To
the dissolved samples chloramine-T reagent (0.282 g
chloramine-T [Sigma], 1 ml deionized water, 1 ml n-propanol
and 8 ml stock buffer) and DMBA reagent (2 g dimethylami-
nobenzaldehyde [Sigma], 1.25 ml n-propanol, and 2.75 ml
perchloric acid) were added. Hydroxyproline content was
measured spectrophotometrically at 550 nm with reference
at 650 nmand normalized to theDNAcontent in the pellet. As
a standard, hydroxyproline (Sigma) was used. All samples
were made in duplicates.
RNA ISOLATION
Total RNAwasextracted from cells cultured inML (1!106)
or from pellets at day 7 and 14. The pellets were collected in
1.5 ml micro tube (Greiner) containing RLT buffer and
disrupted by sonication. To shear genomic DNA aQIAshred-
der column (Qiagen) was used prior to RNA cleanup. Total
RNA was extracted by using RNeasy Mini Kit (Qiagen)
according to the protocol provided by the manufacturer.
MICROARRAYS
Two micrograms of total RNA was used for RNA ampli-
ﬁcation and labeling by the methods of Eberwine et al.27
and Baugh et al.28 with some modiﬁcations29. Labeled and
fragmented ampliﬁed RNA (aRNA) was diluted in 800 ml
hybridization solution and hybridized over night onto CART-
CHIP 300microarray (Millenium Biologix AG) in a provided
hybridization chamber at 42(C according to the protocol
provided by the manufacturer29. The hybridization chamber
used within the current studies has been designed to ﬁt into
a PCR thermal cycler in order to provide minimal tempera-
ture variations and optimal heat transfer during the hybrid-
ization process.
Subsequently microarray slides were washed and dried
for data acquisition in a 418Microarray Scanner (Affymetrix).
DATA ANALYSIS
Data analysis and data normalization were performed
based on the method described by Quackenbush et al.30.
Quantitative spot intensity was determined for all 12 samples
by adding up the pixel intensities within a gene representing
a spot. For background correction the mean intensity of the
spot surrounding area was subtracted for each spot (local
area background). Data sets were normalized by dividing the
mean intensity value of every spot’s duplicate by sum of all
527Osteoarthritis and Cartilage Vol. 12, No. 7spot intensities within a sample to eliminate experimental or
data acquisition variations. Normalized data were directly
used to calculate gene expression level ratios between
different culture stages. Two-fold change threshold was set
to exclude unspeciﬁc ratios.
For hierarchical gene cluster analysis ratios were calcu-
lated for every gene to the median value of all samples within
a distinct gene and performed according to the method of
Eisen et al.31. Genes as well as expression proﬁles for all
samples were clustered with uncentered correlation.
STATISTICS
The biochemical analyses of the pellets were made in
duplicates from all four donors. The values are presented as
meanGSD. Changes in GAG/DNA and HP/DNA from day 7
to 14 were analyzed with the Wilcoxon paired signed rank
test. Values of P!0:05 were considered to indicate
statistically signiﬁcant differences.
Results
BIOCHEMICAL ANALYSIS AND HISTOLOGY
Redifferentiation of the expanded chondrocytes [Fig.
1(A)] was performed by pelleting the cells into micromasscultures in polypropylene tubes in serum free culture
medium. Immediately after centrifugation the cells aggre-
gated into a ﬂat disk that gradually expanded in size into
a rounded pellet [Fig. 1(B)]. The expansion in size of the
pellet during the culture period was accompanied with
accumulation of increasing amounts of cartilage matrix as
demonstrated by biochemical analysis of total proteogly-
cans and collagens [Fig. 2(A and B)]. In addition, matu-
ration of the pellets was shown by decreasing cell density
and increasing Safranin-O staining of proteoglycans and
Fig. 1. Monolayer (2D) and pellet (3D) culture of human articular
chondrocytes. (A) Phase contrast picture of passage 1 human
articular chondrocytes and (B) macroscopic picture of day 6 pellet
in 15 ml polypropylene tubes.0
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Fig. 2. Glycosaminoglycan (GAG) and hydroxyproline (HP) content normalized to the DNA amount of pellets from donors 1 to 4 at day 7 and
14. (A) The amount of GAG/DNA increased in all donors from day 7 to 14. (B) The amount of HP/DNA as a measurement of total collagen
secretion per cell increased in donors 2 and 3 between day 7 and 14, while in donors 1 and 4 it remained at a constant level. An asterisk (*)
indicates statistically signiﬁcant difference between day 7 and 14.
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The presence of high amounts of collagen type II and
a strong staining with Safranin-O as shown in Fig. 2
provide evidence that the chondrocytes have redifferenti-
ated into a cartilage like phenotype.
The change in pattern of collagen type I staining from
a homogenous staining at day 7 into a perichondreal like
staining surrounding the type II rich matrix, further indicate
an ongoing maturation of the pellets towards a cartilage like
tissue [Fig. 3(AeD)]. Assays of total DNA showed no
difference between day 7 and 14, indicating that the
process of redifferentiation took place without change in
cell number (data not shown).
MICROARRAYS
Two major dendogram branches were found when gene
expression proﬁles of all four donor samples from different
time points were clustered with uncentered correlation
[Fig. 4(A)]. Group 1 contained expression proﬁles of
proliferated chondrocytes as well as chondrocytes cultured
for 7 days in pellet culture, whereas group 2 consisted of
expression proﬁles of chondrocytes cultured for 14 days.
Interestingly one sample proﬁle from Donor2 ML was
clustered in a separate branch indicating a different gene
expression proﬁle with respect to the proliferated sample
from the other donors. The other proﬁles of Donor2 (day 7
and 14) were clustered in group 1 and group 2, respectively.
The current gene expression analysis revealed that
approximately half of the 336 genes provided on the micro-
array were either induced or repressed. Fig. 4(B) shows
a selected subset of 98 genes out of 336 representing
similarities in gene expression pattern within different sam-
ples. Genes (rows) were clustered with uncentered correla-
tion. The samples (columns) remained unclustered to point
out consistencies and differences between all donors.
Fig. 3. Histological sections of pellets from Donor2 at day 7 and 14.
The Safranin-O staining for glycosaminoglycan (GAG) showed
increasing amounts from day 7 to 14 (A,C). The increase in matrix
proteins production resulted in a lower cell density in the in vitro
formed tissue. The increase in GAG from day 7 to 14 was
accompanied by an increase in immunoreactivity collagen type II
(green) (B,D) and a decrease in collagen type I (pink) (B,D).The majority of the expressed genes in Fig. 4(B) marked
with bars a and b show a characteristic gene expression
pattern for corresponding time points from the different
donors, indicating maturation process relevant genes. Major
changes were found from day 7 to 14 (late phase), whereas
only few expression changes can be seen between ML and
day 7 (early phase). Most of the selected genes shown in
the matrix in Fig. 4(B) are either up- or downregulated
during the late phase, but also regions that do not show any
obvious changes within all samples can be seen. Outside
the marked regions a and b are shown in Fig. 4(B), some
differentially expressed genes may be associated with
a patient speciﬁc expression pattern.
When the gene expression ratios of individual genes
were calculated between the pellets and ML cultures for all
336 genes, 133 showed a signiﬁcant change in at least 3
out of 4 donors. Table I shows 97 of these genes, selected
by extended literature review to be described in relation to
cartilage or chondrocytes. In the table the genes are
functionally grouped accordingly, from one time point to
the other, providing all the gene expression ratios for each
time point including genes that did not change during
a previous or later time point. From this table either
a speciﬁc expression proﬁle for a certain maturation phase
can be deduced.
In order to identify speciﬁc genes for the early and late
phases, genes from Table I, which were signiﬁcantly chan-
ged in either of the phases, were selected into early and late
genes and plotted against each other and displayed in
a scatter plot [Fig. 5(A and B)]. The early phase contained 9
genes which were speciﬁcally and signiﬁcantly changed
while the late phase included 48 genes, illustrating larger
similarities in gene expression betweenML and day 7 pellets
than day 7 and 14 pellets, conﬁrming the results from the
cluster analysis.
Discussion
Autologous culture expanded chondrocytes, isolated from
full depth biopsies have been used in our lab since 1987 for
repair of cartilage defects with promising long term results32.
In thismethod, amixed population of cells is transplanted into
an in vivo bioreactor, formed by a periosteal ﬂap and the
surrounding cartilage, within the joint. In this environment the
cells aggregate, attach and start to buildmatrix33,34. The high
number of cells used for implantation (1!106=cm2) pro-
motes chondrogenic redifferentiation, since they support
cellecell interactions35. In this study, by using microarray
technology, we have shown that expanded human chon-
drocytes redifferentiate in an in vitro model and form stable
cartilage like constructs. During this dynamic process, the
cells express many of the genes associated with early
chondrogenesis indicating that even differentiated cells are
capable of reinitiating the process. This has an important
implication with respect to the clinical use of cell based
therapies for regeneration of cartilage defects.
Because of the genetic variability among individuals,
many investigators have chosen to pool RNA samples from
different donors before use in a cDNA array analysis36.
Other studies have evaluated RNA samples separately
and used either average changes in gene expression or
changes in gene expression found in the majority of their
samples37. In our study we decided to analyze the RNA
samples from four individuals that underwent ACT treatment
separately. By using this approach we were able to study
both similarities and differences between the donors in the
529Osteoarthritis and Cartilage Vol. 12, No. 7Fig. 4. Variation in expression of 336 genes in 12 experimental
samples. Data are presented in amatrix format: each row represents
a single gene, and each column an experimental sample. In each
sample, the ratio of the abundance of transcripts per gene to the
median abundance of the gene’s transcript among all the different
cell samples is presented by the color of the corresponding matrix.
Green squares, transcript levels below the median; black squares,
transcripts levels equal to the median; red squares, transcript levels
greater than the median. Color intensity/saturation reﬂects thegene expression proﬁles during the redifferentiation
process.
Regarding the performed microarray analysis within the
current study we do not believe that the differences in gene
expression ratios between the donors are caused by
technical shortcomings. The oligonucleotides used within
the current microarrays are spotted in duplicates and this
drastically reduces the risk of false-positive signals caused
by ﬂuorescent particles. Additionally, the use of a controlled
environment allowing a streamlined and accurate sample
processing is indispensable for reproducible and reliable
hybridization experiments. For this reason the ampliﬁedRNA
samples were hybridized in a T-Gradient PCR thermal cycler
(Whatman Biometra) in a hybridization chamber (Millenium
Biologix) specially developed to ensure precise temperature
and volume control. We also used one single round of
ampliﬁcation which has been suggested to be generally used
for all RNA specimens prior to microarray-based gene
expression analysis to improve data quality and detection
of differentially expressed genes38. In order to validate the
ampliﬁcation protocol for our microarrays, we performed
ampliﬁcation reactions under different conditions. We found
that the ampliﬁcation of mRNA could be performed in a very
robust manner with low experimental variations for varying
RNA starting amounts as well as different microarray
slides39. For this purpose, 0.5 up to 2 mg of total RNA was
ampliﬁed and hybridized onto two microarray slides. Spot
intensity ratios of both arrays were calculated as described
before and correlated with a correlation coefﬁcient of 0.9.
These results are in accordance with the literature where
similar experiments with even lower amounts of starting RNA
have been used and compared28. The described protocol
thereof, offers a reasonable reproducibility when the amount
of RNA starting material is limited, especially when isolated
from pellet cultures.
During the embryonic formation of the skeleton, the
differentiation of the chondrogenic mesenchyme can be
divided into three sequential phases: epithelialemesen-
chymal interaction, condensation and differentiation, each
phase consisting of speciﬁc cellular events and molecular
characteristics. Similar phases could be observed during the
redifferentiation of chondrocytes in the pellet model used
within the current study. While expanded chondrocytes
showed a ﬂat ﬁbroblast looking morphology, cells cultured
as pellets turned into a round matrix secreting cell popula-
tion [Figs. 1(B) and 3]. After the initial morphogenesis, the
chondrocytes started to express collagen proteins and at day
7 high expression of collagen type I was observed in the
whole pellet. This expression was changed into collagen
type II at day 14 (Fig. 3). Furthermore, the collagen type I
expression was at day 14 limited to the ﬂat cells surround-
ing the collagen type II matrix, imitating a formation of a
magnitude of the ratio relative to the median for each set of samples
(see scale, top right). (A) Dendogram showing clustered samples
according to their gene expression proﬁle. Samples with similar gene
expression proﬁles are located in a speciﬁc branch. In general, two
main branches can be seen. Group 1 including ML and day 7
samples and group 2 consisting of samples from pellets cultured for
14 days. Only one sample (Donor2 ML) was clustered in a separate
branch. (B) Gene expression matrix representing similarities in gene
expression patterns between different experimental samples. A
representative subset of 98 genes is shown. Geneswith similar gene
expression levels were clustered together. Expression proﬁles
remained unclustered to illustrate differences in gene expression
within donors. Two speciﬁc gene clusters showing differences
between ML cells, day 7 and 14 pellets are indicated as bar a and b.
Table I
G roups and the ratios are shown for all donors
kers of the ‘‘late’’ phase are indicated with L
N ay 14 Marker
Don 2 Don 3 Don 4
M
X 4,27 2,36 2,99 L
X 6,21 6,57 19,25 L
J 4,26 2,46 11,61
X 1,59 2,10 2,45 L
N 12,70 2,31 1,50
X 6,01 1,68 3,95
Z 8,32 26,57 60,33
X 44,80 1,53 3,79
N 5,51 10,57 6,36 L
X 2,11 3,31 7,72 L
N 3,08 2,43 2,54 L
X 2,95 3,68 1,62 L
X 2,43 3,04 4,72 L
X 2,04 2,76 2,30 L
M
N 2,56 2,33 2,30 L
X 4,67 10,10 23,27
N 13,27 11,53 19,82 L
N 1,56 1,64 2,91
N 2,02 3,62 7,37 L
X 13,85 10,09 23,45 L
X 3,24 2,81 10,84 L
U 2,78 3,87 6,55 L
N 4,75 6,50 13,15 L
X 1,70 2,43 2,25
In
N 1,71 2,05 2,81 L
N 2,60 2,33 5,48 L
X 1,34 5,20 6,19 L
X 2,65 3,06 3,31
L 4,53 3,51 4,93 L
U 1,33 1,85 1,02 E
N 2,69 1,87 1,77 E
C
N 8,39 7,44 19,79 L
X 2,63 3,09 3,23
N 4,11 1,85 1,37
L 2,55 2,44 3,71 L
D
X 15,42 14,99 34,31 L
X 1,54 3,54 4,30 L
U 2,29 3,02 3,62 L
M 1,98 2,62 2,48
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Don 1 Don 2 Don 3 Don 4 Don 1
atrix proteins
M_042153 Biglycan (BGN) 1,06 1,23 1,65 1,29 3,25
60382 Collagen, type X, alpha-1 (COL10A1) 1,26 1,15 1,47 1,40 4,14
04177 Collagen type XI alpha-1 (COL11A1) 1,59 11,02 2,88 5,76 1,16
M_036175 Collagen, type XVIII, alpha 1 (COL18A1) 1,86 1,63 1,27 1,73 3,51
M_002160 Hexabrachion (tenascin C, cytotactin) (HXB) 5,99 9,49 2,54 2,14 9,34
M_009336 Cartilage oligomeric matrix protein (COMP) 2,32 2,77 4,16 11,02 8,82
22865 Dermatopontin 6,26 7,49 16,88 34,40 11,37
M_055254 Fibronectin 1 (FN1) 6,60 31,20 3,57 8,58 5,02
M_005506 CD36 antigen (collagen type I receptor) (CD36L2) 3,17 1,19 1,19 1,18 7,61
M_002321 Glypican 1 (GPC1) 1,03 2,09 1,49 1,27 2,80
M_002379 Matrilin 1 (MATN1) 1,06 1,74 1,00 2,58 1,62
M_029245 Collagen, type I (COL1A2) 1,69 6,67 1,32 1,04 2,36
M_054566 Collagen, type VI (COL6A1) 1,08 1,76 1,60 1,73 1,97
M_037965 Chondroadherin (CHAD) 1,23 2,59 1,08 1,91 1,55
etalloproteinases
M_002421 Matrix metalloproteinase 1 (MMP1) 1,16 3,44 1,08 1,64 1,10
M_017384 Matrix metalloproteinase 7 (MMP7) 6,89 2,82 3,27 6,73 9,74
M_002424 Matrix metalloproteinase 8 (MMP8) 1,52 1,06 1,20 1,34 9,76
M_004995 Matrix metalloproteinase 14 (MMP14) 1,27 4,09 1,40 1,64 1,73
M_001912 Cathepsin L (CTSL) 1,22 1,86 1,56 1,16 2,95
M_006121 Cathepsin D (CTSD) 1,54 1,15 1,18 1,37 7,67
M_085705 Tissue inhibitor of metalloproteinase 2 (TIMP2) 1,51 1,43 1,13 1,04 2,08
09577 Lysosomal hyaluronidase (LUCA2/HYAL2) 1,51 1,38 1,23 1,27 3,55
M_005186 Calpain 1 (mu/I) large subunit (CAPN1) 1,11 1,34 1,66 1,48 3,32
M_035662 Cathepsin B (CTSB)* 1,88 4,20 1,99 1,88 2,44
tegrins
M_000632 Integrin, alpha M (CD11b) 2,22 1,30 1,18 1,29 2,31
M_002211 Integrin, beta 1 (ﬁbronectin receptor, CD29) (ITGB1) 1,00 1,10 1,09 1,96 2,67
M_003913 Integrin, alpha 2 (CD49B) (ITGA2) 1,17 5,16 1,08 1,64 4,35
M_036107 Integrin, beta 2 antigen CD18 (p95) (ITGB2) 5,96 1,33 2,17 4,70 2,48
13616 Focal adhesion kinase (FAK) 1,03 1,20 1,09 1,32 2,69
59289 H-cadherin 1,03 2,52 2,05 3,12 2,06
M_080682 Vascular cell adhesion molecule 1 (VCAM1) 2,39 3,25 2,25 6,79 1,01
ell cycle
M_002094 G1 to S phase transition 1 (GSPT1) 1,30 1,97 1,37 1,39 5,41
M_042664 Nuclear autoantigenic sperm protein (NASP) 2,40 6,41 2,30 1,64 1,18
M_007306 Breast cancer 1, early onset (BRCA1) 1,30 3,97 1,58 1,64 1,95
13720 Growth-arrest-speciﬁc protein (gas) 1,07 2,31 1,07 1,96 2,00
evelopment
60188 ERK-1 for protein serine/threonine kinase 1,15 1,14 1,21 1,44 14,01
M_039094 SRY (sex determining region Y)-box 9 (SOX9) 1,73 1,05 1,15 2,94 4,84
92268 Mitogen activated protein kinase p38-2 1,82 2,73 1,33 1,89 2,73
97676 Homeobox protein (region 7) (HOX7) 1,04 3,02 1,08 8,01 1,61
Apoptosis
XM_054686 Caspase 3, apoptosis-related cysteine protease (CASP3) 1,20 1,10 1,15 1,12 4,69 23,24 5,65 7,36 L
M13994 B-cell leukemia/lymphoma 2 (bcl-2) bcl-2-alpha protein 1,31 1,21 1,50 1,60 4,27 5,36 6,25 7,82 L
8 3,28 2,14 9,32 1,23 2,13 1,21 1,36 E
3 1,02 1,20 1,34 6,87 10,46 7,91 15,63 L
2 3,23 1,01 1,64 2,60 1,08 3,58 3,03 L
2 1,03 1,37 1,45 9,07 13,24 13,24 26,67 L
8 5,61 1,08 1,64 1,74 3,38 2,86 2,89 L
6 1,22 1,39 1,54 3,40 2,08 4,08 11,03 L
5 1,26 1,29 1,36 2,18 1,25 4,27 6,21 L
4 2,76 1,09 1,05 22,15 8,15 26,24 73,51 L
6 1,48 1,24 1,11 6,20 4,45 3,54 3,52 L
2 3,19 1,40 1,02 2,94 1,36 3,43 5,83 L
1 1,33 1,17 1,35 4,59 4,09 7,03 6,62 L
5 1,28 1,05 1,01 9,89 6,63 12,20 24,49 L
7 1,89 1,35 1,11 1,85 5,96 4,23 15,15 L
3 1,63 1,41 1,32 3,44 5,97 5,36 14,27 L
7 2,02 2,31 3,65 2,45 1,12 1,62 1,44 E
0 1,82 1,46 1,33 6,09 7,92 7,28 16,75 L
9 1,63 3,15 3,91 6,81 3,12 8,01 12,02
3 1,53 1,23 1,14 4,36 3,35 5,51 7,74 L
0 3,02 1,08 1,64 1,45 2,25 5,38 5,44 L
3 1,13 1,16 1,31 8,04 2,64 5,82 1,78 L
3 2,27 1,04 1,22 1,62 2,71 2,49 2,57 L
9 2,61 1,86 3,77 1,34 1,23 3,51 1,60 E
8 1,67 1,15 1,01 11,19 8,57 12,49 24,56 L
4 1,68 1,13 1,15 3,88 4,19 3,80 8,36 L
5 1,09 1,68 1,88 2,63 5,32 4,70 10,52 L
0 4,77 1,77 1,64 1,21 2,15 2,96 4,10 L
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7XM_017591 Annexin A6 (ANXA6) 1,6
Growth and cell stimulating factors
U13660 Cartilage-derived morphogenetic protein 1 (CDMP-1) 1,3
XM_031221 Interleukin 1, alpha (IL1A) 1,5
XM_003752 Interleukin 3 (colony-stimulating factor, multiple) (IL3) 1,2
XM_031289 Interleukin 8 (IL8) 1,3
U63717 Osteoclast stimulating factor 1,1
M92934 Connective tissue growth factor 1,2
J00306 Somatostatin I gene and ﬂanks 1,7
X00129 Retinol binding protein (RBP) 1,4
X06614 Receptor of retinoic acid 1,0
Metabolism
AF189279 Group IIE secretory phospholipase A2 1,0
S79854 Type 3 iodothyronine deiodinase 1,6
U37012 Cleavage and polyadenylation speciﬁcity factor 1,3
U43747 Frataxin (FRDA) 1,1
X58957 Agammaglobulinaemia tyrosine kinase 1,1
XM_046765 Thymidylate synthetase (TYMS) 1,1
XM_048201 Metallothionein 1L (MT1L) 8,6
XM_086368 MUF1 protein (MUF1) 1,3
K00065 Superoxide dismutase (SOD-1) 1,3
Transcription and signaling factors
M58549 Matrix Gla protein (MGP) 1,4
AF037204 RING zinc ﬁnger protein (RZF) 1,0
D49835 DNA-binding protein 2,2
NM_014470 GTP-binding protein (RHO6) 1,7
U13991 TATA-binding protein, 30 kDa subunit (tafII30) 1,1
U38864 Zinc-ﬁnger protein C2H2-150 1,0
U45975 Phosphatidylinositol (4,5)bisphosphate 5-phosphatase 1,1
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Fig. 5. Scatter plot analysis of genes expressed during the early (ML to day 7) and the late phase (day 7 to 14) of the in-vitro redifferentiation
period. Early and late marker genes were deﬁned as speciﬁc genes that showed at least a two-fold change in the gene expression level and
a similar expression proﬁle in at least 3 out of 4 donors (based on average values of patient to patient variation) exclusively in the deﬁned time
period. (A) Scatter plot of genes that were classiﬁed as early markers (9) and (B) as late markers (48) (for additional information see also Table I).perichondrium like layer. A similar change or remodeling in
cartilage matrix composition has been observed in biopsies
taken from transplanted areas from patients treated with
ACT40,41. This could indicate that the maturation process in
the pellet model is representative for the in vivo conditions in
the joint.
The changes between the early phase and the late phase
that were seen at the protein level were also observed in
gene expression by the cluster analysis. However, the
change of gene expression levels from ML until day 7
included fewer genes than from day 7 until day 14 [see also
Fig. 5(A and B)], which may indicate that the early phase in
the pellet culture is a ‘‘quiet phase’’ and that the real
redifferentiation takes place after day 7.
Genes which were upregulated in the early phase, were
genes coding for matrix proteins like collagen type XI,
dermatopontin, COMP, while glypican was especially
upregulated for Donor2. The increased expression of
dermatopontin has also previously been described during
differentiation of MSCs towards the chondrogenic lineage18.
The function of this recently described 22 kDa protein is
relatively unclear but it has been reported to interact with
decorin42, to accelerate collagen ﬁbrillogenesis and to
enhance and modify the behavior of TGF-b43.
Other genes that were upregulated in the early phase for
some of the donors were genes that have been associated
with the development of OA. Matrix metalloproteinase 7
(MMP-7) has been shown to be overexpressed in human
OA cartilage44 as well as tenascin-C45 and ﬁbronectin46.
Tenascin that has been shown to be present in the dense
mesenchyme surrounding developing epithelia, in tendon
anlagen and in developing cartilage and bone47, could
indicate the start of the development of new tissue.
Fragments of ﬁbronectin have further been shown to
enhance the catabolic activity of articular chondrocytes48.As already pointed out and shown in Fig. 5(B), the majority
of genes changed their geneexpression levels during the late
phase from day 7 to 14. Among genes which increased in
expression during the late phase were collagen types I, VI,
XVIII, Matrilin1 and chondroadherin, while TIMP2 andMMP8
were strongly downregulated indicating dynamic regulations
of proteases and inhibitors thereof49. Other genes involved in
the modulation and maturation of cartilage matrix that
showed differential regulation were the cystein rich pro-
teolytic cathepsins. These enzymes have been shown to
increase in ML cultures of articular chondrocytes50 and to
have differential distribution in articular cartilage during
skeletal development51. Cathepsin D, which has further
been immunolocalized in hypertrophic chondrocytes adja-
cent to the osteochondral junction52 was together with
cathepsin L downregulated in our in vitro experiment while
cathepsin B was upregulated after day 7.
With respect to the cell cycle we found that genes like
GSPT1, which controls G1 to the S phase transition53, and
growth-arrest-speciﬁc protein54 were strongly up-respec-
tively downregulated between 7 and 14 days, thus being
in accordance with the transition from the proliferative
phase in monolayer to a tissue forming process. Other signs
of a change towards a more differentiated and organized
structure, were the strong downregulation of the cell
adhesion molecules FAK and the Integrin beta 1 (ﬁbronectin
receptor).
In the developing skeleton and during endochondral bone
formation, the maturation of chondrocytes is characterized
by hypertrophy, apoptosis, mineralization and bone forma-
tion. During this maturation a number of genes like collagen
type X and Matrix Gla protein are expressed55. Our data
show downregulation of the expression of the genes
mentioned above, indicating that the maturation in the pellet
system happened without any signs of hypertrophy.
533Osteoarthritis and Cartilage Vol. 12, No. 7The pellets did further mature without changes in cell
numbers indicating potentially no involvement of necrosis
and/or apoptosis as shown by the constant amount of DNA
in the pellets (data not shown) and decreased expression of
caspase 3.
Interestingly, the gene expression during the maturation
process in the pellets mimicked the signaling processes
involved in the early chondrogenesis shown in micromass
cultures with cells isolated from embryonic limb buds.
Especially we observed a signiﬁcant decrease between
day 7 and 14 of the expression of retinoic acid receptor
(RAR) which proceeds the intracellular signaling processes,
such as activation of p38 kinase and inhibition of extra
cellular signal-regulated protein kinase (ERK-1), known to
be involved in the regulation of SOX-9 expression56. While
expression of the RAR has been shown to attenuate
redifferentiation, SOX-9 plays an essential role in establish-
ing the precartilaginous condensation and in initiating
chondroblast differentiation57. Our results from the micro-
array analysis showed a strong downregulation of ERK-1
and upregulation of p38 kinase and SOX-9 suggesting that
the signaling cascade is activated during the redifferentia-
tion and maturation process of adult chondrocytes in vitro.
Other genes expressed during the embryonic limb
formation are the HOX genes. These genes are involved in
the formation of digits and are suggested to be regulated by
retinoic acid via direct control of cdx158. In our microarray
analysis we studied two of theHOXgenes of which theMsx-1
(formerly HOX-7) was upregulated during the late phase.
Regarding speciﬁc differences in gene expression levels
between different donors we have found that for Donor2 the
gene expression proﬁle of ML cultures differed signiﬁcantly
from other cultures as shown in Fig. 4(A), while samples from
day 7 and 14 were grouped accordingly with the other
donors. Especially Collagen type I and XI, tenascin C and
ﬁbronectin were strongly upregulated on day 7, while RAR-
responder-proteins were strongly downregulated compared
to the other samples, potentially indicating an earlier
predisposition to the redifferentiation process. Alternatively
it may be postulated that either the cells were in a different
state when isolated from the tissue (patient history unknown)
or that the culture conditions like e.g., autologous serum had
different effects on the cells resulting in a differentially
expressed and characterized gene expression proﬁle.
Another possibility is that difference between the donors
could be associated with the depth of the biopsy, reﬂecting
different cell sources or populations that may be present after
the tissue has been digested. The cells used in this study
(surplus cells from ACT treatment) originate from full depth
biopsies taken from non-weight bearing areas in the joint, but
the techniques for obtaining biopsies could slightly differ
even between experienced surgeons. The cultures may
therefore contain amixed population of cells representing the
characteristics from the different layers of cartilage59. This
could also be an explanation for the simultaneous production
of collagen type II richmatrix and expression of both primitive
and mature chondrogenic genes. The cells producing
collagen type II may originate from the middle layers while
the cells expressing primitive genes may originate from
chondrogenic progenitors suggested to be found in the
superﬁcial layer of articular cartilage60.
The use of autologous chondrocytes for repair of cartilage
lesions will always result in individual differences in the cells
used for transplantation. In our lab we have expanded cells
from over 1000 biopsies without any failures in the cultures.
However, we do not know if the cells from all patients have
had the same chondrogenic potential. In the current studywe have provided evidence, that by applying microarray
analysis it may be possible to characterize the cell popu-
lation used within an ACT treatment based on its gene
expression proﬁle and to assess the chondrogenic potential
of the expanded cells. These ﬁndings may further be used
as a quality control tool before delivering the cells to the
patient and to ensure to provide cells that are strongly
capable of reinitiating new cartilage tissue formation within
the treated area. Additional information from the gene
expression proﬁles may be deduced that could potentially
allow us to better modify or treat expanded cell culture, in
order to increase their chondrogenic potential before
implantation.
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